델라웨어의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 20개가 델라웨어 내 여러 지역에서 참여자를 모집하고 있습니다.
델라웨어의 도시
공식 연구 텍스트(영어)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center, Newark
피험자 모집 중3상
18세 ~ 100세 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT05920356Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04267848Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, Newark
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07291037A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Medical Oncology Hematology Consultants, PA, Newark
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07144280Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07388524A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Medical Oncology Hematology Consultants, PA, Newark
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07361497Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 외 1개
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06418204A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Newark
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT06692738A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Medical Oncology Hematology Consultants, PA, Newark
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06875310A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- ChristianaCare Health System, Newark
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT07154290Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
피험자 모집 중2상
18 Minutes · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Beebe South Coastal Health Campus, Millville
- Helen F Graham Cancer Center, Newark
- Medical Oncology Hematology Consultants PA, Newark
- 외 1개
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06616584The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Medical Oncology Hematology Consultants, Newark
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04585750A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Newark
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06868277Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
- Bayhealth Cancer Center- Kent, Dover
- Bayhealth Cancer Center- Sussex, Milford
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07028489An External Control Arm Study in Non-Small Cell Lung Cancer
- Bayhealth Medical Center, Kent Campus, Dover
- Bayhealth Medical Center- Sussex Campus, Milford
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07174388Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Bayhealth Hospital Kent Campus, Dover
- Bayhealth Hospital Sussex Campus, Milford
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 3. 업데이트됨 · NCT05642572SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Newark
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.